Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis

The Lancet Global Health

Volumn 4, Issue 8, 2016, Pages e568-e578

  Nayagam, Shevanthi ^a,b   Conteh, Lesong ^b   Sicuri, Elisa ^b,c   Shimakawa, Yusuke ^d,e   Suso, Penda ^d   Tamba, Saydiba ^d   Njie, Ramou ^f   Njai, Harr ^d   Lemoine, Maud ^a,d   Hallett, Timothy B ^b   Thursz, Mark ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^e INSTITUT PASTEUR   (France)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; TENOFOVIR; ANTIVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CONFORMATIONAL TRANSITION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE SIMULATION; ECHOGRAPHY; ELASTOGRAPHY; GAMBIA; HEALTH CARE POLICY; HUMAN; HUMAN EXPERIMENT; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH; SENSITIVITY ANALYSIS; VIRUS LOAD; BLOOD; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOLOGY; MALE; MASS SCREENING; POINT OF CARE SYSTEM; PROCEDURES; QUALITY ADJUSTED LIFE YEAR;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; GAMBIA; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MASS SCREENING; MODELS, ECONOMIC; POINT-OF-CARE SYSTEMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84991660766     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(16)30101-2     Document Type: Article

References (78)

1. 1 Schweitzer, A, Horn, J, Mikolajczyk, RT, Krause, G, Ott, JJ, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
2. 2 Viviani, S, Carrieri, P, Bah, E, et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 17 (2008), 3216–3223.
3. 3 WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/, 2015 (accessed May 23, 2016).
4. 4 WHO. Global policy report on the prevention and control of viral hepatitis in WHO Member States. http://www.who.int/csr/disease/hepatitis/global_report/en/, 2013 (accessed May 23, 2016).
5. 5 Dan, YY, Wong, JB, Hamid, SS, et al. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatol Int 8 (2014), 382–394.
6. 6 Toy, M, Onder, FO, Idilman, R, et al. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 13 (2012), 663–676.
7. 7 Hahne, S, Veldhuijzen, I, Wiessing, L, Lim, T-A, Salminen, M, Laar, Mv, Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis, 13, 2013, 181.
8. 8 WHO. HIV/AIDS: global price reporting mechanism. http://apps.who.int/hiv/amds/price/hdd/ (accessed Sept 7, 2015).
9. 9 WHO. WHO-CHOICE unit cost estimates for service delivery. http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/, 2011 (accessed April 5, 2015).
10. 10 Cremin, I, Cauchemez, S, Garnett, GP, Gregson, S, Patterns of uptake of HIV testing in sub-Saharan Africa in the pre-treatment era. Trop Med Int Health 17 (2012), e26–e37.
11. 11 Rosen, S, Fox, MP, Gill, CJ, Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med, 4, 2007, e298.
12. 12 Mills, EJ, Nachega, JB, Buchan, I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296 (2006), 679–690.
13. 13 Kitrinos, KM, Corsa, A, Liu, Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 59 (2014), 434–442.
14. 14 Papatheodoridis, GV, Manolakopoulos, S, Touloumi, G, et al. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat 22 (2015), 120–127.
15. 15 Wong, GL, Chan, HL, Mak, CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58 (2013), 1537–1547.
16. 16 Njai, HF, Shimakawa, Y, Sanneh, B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. J Clin Microbiol 53 (2015), 1156–1163.
17. 17 Shivkumar, S, Peeling, R, Jafari, Y, Joseph, L, Pai, NP, Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980–2010). Am J Gastroenterol 107 (2012), 1306–1313.
18. 18 WHO. WHO guide to cost-effectiveness analysis, 2003, World Health Organization, Geneva.
19. 19 Bill & Melinda Gates Foundation. Methods for economic evaluation project (MEEP): the Gates reference case, 2014, Bill & Melinda Gates Foundation, Seattle, WA.
20. 20 Fattovich, G, Bortolotti, F, Donato, F, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008), 335–352.
21. 21 Chang, M-H, Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 15 (2000), E16–E19.
22. 22 Fattovich, GBL, Giustina, G, Noventa, F, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 32 (1991), 294–298.
23. 23 Chen, CJ, Yang, HI, Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26 (2011), 628–638.
24. 24 Tseng, TC, Liu, CJ, Chen, CL, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 205 (2012), 54–63.
25. 25 Liaw, YF, Tai, DI, Chu, CM, Chen, TJ, The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988), 493–496.
26. 26 Ikeda, K, Saitoh, S, Suzuki, Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 28 (1998), 930–938.
27. 27 Wu, G, Zhou, W, Zhao, Y, et al. Study on the natural history of chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 10 (2002), 46–48 (in Chinese).
28. 28 Lo, KJ, Tong, MJ, Chien, MC, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 146 (1982), 205–210.
29. 29 Lin, HH, Liaw, YF, Chen, TJ, Chu, CM, Huang, MJ, Natural course of patients with chronic type B hepatitis following acute hepatitis delta virus superinfection. Liver 9 (1989), 129–134.
30. 30 Huo, T, Wu, JC, Hwang, SJ, et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol 12 (2000), 687–693.
31. 31 Chen, TJ, Liaw, YF, The prognostic significance of bridging hepatic necrosis in chronic type B hepatitis: a histopathologic study. Liver 8 (1988), 10–16.
32. 32 Beasley, RP, Hwang, LY, Lin, CC, Chien, CS, Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 318 (1981), 1129–1133.
33. 33 Beasley, RP, Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988), 1942–1956.
34. 34 Liaw, YF, Tai, DI, Chu, CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 90 (1986), 263–267.
35. 35 Xu, B, Hu, D-C, Rosenberg, DM, et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 18 (2003), 1345–1352.
36. 36 Chu, CM, Liaw, YF, Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 104 (2009), 1693–1699.
37. 37 Chu, CM, Hung, SJ, Lin, J, Tai, DI, Liaw, YF, Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 116 (2004), 829–834.
38. 38 Chu, CM, Liaw, YF, HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 45 (2007), 1187–1192.
39. 39 Gigi, E, Lalla, T, Orphanou, E, Sinakos, E, Vrettou, E, Raptopoulou-Gigi, M, Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece. J Gastrointestin Liver Dis 16 (2007), 19–22.
40. 40 Chu, CM, Liaw, YF, Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43 (2005), 411–417.
41. 41 Papatheodoridis, GV, Chrysanthos, N, Hadziyannis, E, Cholongitas, E, Manesis, EK, Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 15 (2008), 434–441.
42. 42 Chen, JD, Yang, HI, Iloeje, UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138 (2010), 1747–1754.
43. 43 Zacharakis, GH, Koskinas, J, Kotsiou, S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 77 (2005), 173–179.
44. 44 Hsu, YS, Chien, RN, Yeh, CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35 (2002), 1522–1527.
45. 45 Fattovich, G, Pantalena, M, Zagni, I, Realdi, G, Schalm, SW, Christensen, E, Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97 (2002), 2886–2895.
46. 46 Liaw, YF, Lin, DY, Chen, TJ, Chu, CM, Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 9 (1989), 235–241.
47. 47 Liaw, Y-F, Sung, J, Chow, W, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004), 1521–1531.
48. 48 Tong, MJ, Hsien, C, Song, JJ, et al. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 54 (2009), 1337–1346.
49. 49 Tong, MJ, Hsien, C, Hsu, L, Sun, HE, Blatt, LM, Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 48 (2008), 1070–1078.
50. 50 Chen, YC, Chu, CM, Yeh, CT, Liaw, YF, Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 1 (2007), 267–273.
51. 51 Kobayashi, M, Ikeda, K, Hosaka, T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 78 (2006), 459–465.
52. 52 Mahmood, S, Niiyama, G, Kamei, A, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 25 (2005), 220–225.
53. 53 Tsai, JF, Jeng, JE, Ho, MS, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 76 (1997), 968–974.
54. 54 Chen, D-S, Hepatitis B and C virus infections in hepatocellular carcinoma and their prevention. Nishioka, K, Suzuki, H, Mishiro, S, Oda, T, (eds.), 1994, Springer Japan, Viral hepatitis and liver disease, 685–689.
55. 55 Ikeda, K, Saitoh, S, Koida, I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18 (1993), 47–53.
56. 56 Obata, H, Hayashi, N, Motoike, Y, et al. A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection. Int J Cancer 25 (1980), 741–747.
57. 57 Lin, X, Robinson, NJ, Thursz, M, et al. Chronic hepatitis B virus infection in the Asia–Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 20 (2005), 833–843.
58. 58 Hui, AY, Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 34 (2002), 569–572.
59. 59 Salomon, JA, Vos, T, Hogan, DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2129–2143.
60. 60 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50 (2009), 227–242.
61. 61 Lemoine, M, Shimakawa, Y, Njie, R, et al. Screen and treat as an intervention programme for 1 hepatitis B virus infection in sub-Saharan Africa: the PROLIFICA experience in The Gambia. Lancet Glob Health 4 (2016), e559–e567.
62. 62 United Nations Department of Economic and Social Affairs, Population Division. World population prospects: the 2012 Revision, DVD Edition. http://esa.un.org/unpd/wpp/ (accessed Dec 5, 2014).
63. 63 Levy, AR, Kowdley, KV, Iloeje, U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 11 (2008), 527–538.
64. 64 WHO. Cost effectiveness and strategic planning: choosing interventions that are cost-effective. http://www.who.int/choice/en/, 2014 (accessed May 23, 2016).
65. 65 Shillcutt, SD, Walker, DG, Goodman, CA, Mills, AJ, Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 27 (2009), 903–917.
66. 66 Marseille, E, Larson, B, Kazi, DS, Kahn, JG, Rosen, S, Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 93 (2015), 118–124.
67. 67 UN data USD. Gambia: country profile. http://data.un.org/CountryProfile.aspx?crName=gambia, 2014 (accessed Oct 8, 2014).
68. 68 MSF Access Campaign. Untangling the web of antiretroviral price reductions: 17th Edition. http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-17th-edition-%E2%80%93-july-2014, 2014 (accessed May 23, 2016).
69. 69 Ong, SC, Mak, B, Aung, MO, Li, SC, Lim, SG, Health-related quality of life in chronic hepatitis B patients. Hepatology 47 (2008), 1108–1117.
70. 70 Berg, T, Simon, KG, Mauss, S, et al. O119: Stopping tenofovir disoproxil fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: week 48 interim results from an ongoing randomized, controlled trial (“finite CHB”). J Hepatol, 62(suppl 2), 2015, S253.
71. 71 Suthar, AB, Ford, N, Bachanas, PJ, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med, 10, 2013, e1001496.
72. 72 Hill, A, Gotham, D, Cooke, G, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Erad 1 (2015), 103–110.
73. 73 Whittle, H, Jaffar, S, Wansbrough, M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ, 325, 2002, 569.
74. 74 Chotiyaputta, W, Hongthanakorn, C, Oberhelman, K, Fontana, RJ, Licari, T, Lok, AS, Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 19 (2012), 205–212.
75. 75 Shimakawa, Y, Lemoine, M, Njai, HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut, 2015, 10.1136/gutjnl-2015-309892 published online July 16.
76. 76 Shimakawa, Y, Lemoine, M, Bottomley, C, et al. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Liver Int 35 (2015), 2318–2326.
77. 77 Kim, S-Y, Lee, G, Goldie, S, Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect Dis, 10, 2010, 260.
78. 78 Nayagam S, Thursz M, Sicuri E, et al. Requirements for the global elimination of hepatitis B: a modelling study. Lancet Infect Dis (in press).